MannKind Corporation has signed an agreement with Tanner Pharma Group for distribution of Afrezza inhaled insulin in regions outside of the US, the company said. The agreement covers regions where Afrezza is not yet approved, and Tanner Pharma Group subsidiary TannerGAP will manage the distribution in those areas.
In 2017, Mannkind announced that Biomm would distribute Afrezza in Brazil and in May of this year, the company said that Cipla would distribute the drug in India.
Tanner Pharma Group Chairman and Founder Banks Bourne said, “We are pleased to partner with MannKind in helping fulfill the demand for Afrezza in countries outside the US.”
MannKind CEO Michael Castagna said, “Al Mann had a vision of making Afrezza available to all people living with diabetes around the world and this agreement helps accelerate that access to Afrezza on a named patient access basis in underserved international markets. Our partnership with Tanner Pharma to distribute Afrezza provides us a strong partner with a track record of success in working with physicians, hospitals and ministries of health to provide medicine that is not currently available in their country.”
Read the MannKind Corporation press release.
